Plexision
Plexision, a Pittsburgh-based company, develops cellular biomarkers for personalized diagnosis and drug development in organ transplantation and immunological disorders.
Founded
2008Plexision, a Pittsburgh-based company, develops cellular biomarkers for personalized diagnosis and drug development in organ transplantation and immunological disorders.
Plexision, founded in Pittsburgh, focuses on developing cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. Their core mission is to enhance patient outcomes through precision medicine. The company's flagship product, the Pleximmune™ assay, predicts the risk of transplant rejection by measuring antigen-specific white blood cells. Plexision offers testing services for transplant recipients and drug developers through its CLIA-certified central laboratory.
Notable affiliated individuals include key researchers and medical professionals specializing in immunology and transplantation. Plexision has secured investments from healthcare-focused venture capital firms. Key achievements include the development and patenting of the Pleximmune™ assay, which has significantly impacted the field of transplant medicine by providing a reliable method to predict transplant rejection. Overall, Plexision's innovations have contributed to more personalized and effective treatment plans for transplant patients.
Companies similar to Plexision include Plectix BioSystems, Plexium, Prenosis and Prellis Biologics.
Plexision was founded in 2008.
Plexision's headquarters is located in Pittsburgh, PA, US.
Plexision's most recent funding round was for $218.4k (USD) in September 2020.
As of Sep 1, 2020, Plexision has disclosed funding of $218.4k (USD). Undisclosed round amounts are excluded.
Plexision has 8 employees as of Feb 4, 2024.
Prellis Biologics
prellisbio.com
